Marked Reduction in 30-Day Mortality Among Elderly Patients with Community-acquired Pneumonia



      Community-acquired pneumonia is the most common infectious cause of death in the US. Over the last 2 decades, patient characteristics and clinical care have changed. To understand the impact of these changes, we quantified incidence and mortality trends among elderly adults.


      We used Medicare claims to identify episodes of pneumonia, based on a validated combination of diagnosis codes. Comorbidities were ascertained using the diagnosis codes located on a 1-year look back. Trends in patient characteristics and site of care were compared. The association between year of pneumonia episode and 30-day mortality was then evaluated by logistic regression, with adjustment for age, sex, and comorbidities.


      We identified 2,654,955 cases of pneumonia from 1987-2005. During this period, the proportion treated as inpatients decreased, the proportion aged ≥80 years increased, and the frequency of many comorbidities rose. Adjusted incidence increased to 3096 episodes per 100,000 population in 1999, with some decrease thereafter. Age/sex-adjusted mortality decreased from 13.5% to 9.7%, a relative reduction of 28.1%. Compared with 1987, the risk of mortality decreased through 2005 (adjusted odds ratio, 0.46; 95% confidence interval, 0.44-0.47). This result was robust to a restriction on comorbid diagnoses assessing for the results' sensitivity to increased coding.


      These findings show a marked mortality reduction over time in community-acquired pneumonia patients. We hypothesize that increased pneumococcal and influenza vaccination rates as well as wider use of guideline-concordant antibiotics explain a large portion of this trend. © 2011 Elsevier Inc. All rights reserved.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fine M.J.
        • Auble T.E.
        • Yealy D.M.
        • et al.
        A prediction rule to identify low-risk patients with community-acquired pneumonia.
        N Engl J Med. 1997; 336: 243-250
        • Fry A.M.
        • Shay D.K.
        • Holman R.C.
        • Curns A.T.
        • Anderson L.J.
        Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002.
        JAMA. 2005; 294: 2712-2719
        • Trotter C.L.
        • Stuart J.M.
        • George R.
        • Miller E.
        Increasing hospital admissions for pneumonia, England.
        Emerg Infect Dis. 2008; 14: 727-733
        • Vaccarino V.
        • Parsons L.
        • Peterson E.D.
        • Rogers W.J.
        • Kiefe C.I.
        • Canto J.
        Sex differences in mortality after acute myocardial infarction: changes from 1994 to 2006.
        Arch Intern Med. 2009; 169: 1767-1774
        • Kornum J.B.
        • Thomsen R.W.
        • Riis A.
        • Lervang H.H.
        • Schonheyder H.C.
        • Sorensen H.T.
        Type 2 diabetes and pneumonia outcomes: a population-based cohort study.
        Diabetes Care. 2007; 30: 2251-2257
        • Seymann G.B.
        Community-acquired pneumonia: defining quality care.
        J Hosp Med. 2006; 1: 344-353
        • Baddour L.M.
        • Yu V.L.
        • Klugman K.P.
        • et al.
        Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.
        Am J Respir Crit Care Med. 2004; 170: 440-444
        • Waterer G.W.
        • Somes G.W.
        • Wunderink R.G.
        Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.
        Arch Intern Med. 2001; 161: 1837-1842
        • Ramirez J.A.
        Processes of care for community-acquired pneumonia.
        Infect Dis Clin North Am. 2004; 18: 843-859
        • Meehan T.P.
        • Fine M.J.
        • Krumholz H.M.
        • et al.
        Quality of care, process, and outcomes in elderly patients with pneumonia.
        JAMA. 1997; 278: 2080-2084
        • Fine M.J.
        • Stone R.A.
        • Singer D.E.
        • et al.
        Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study.
        Arch Intern Med. 1999; 159: 970-980
        • Fine J.M.
        • Fine M.J.
        • Galusha D.
        • Petrillo M.
        • Meehan T.P.
        Patient and hospital characteristics associated with recommended processes of care for elderly patients hospitalized with pneumonia: results from the medicare quality indicator system pneumonia module.
        Arch Intern Med. 2002; 162: 827-833
        • Meehan T.P.
        • Weingarten S.R.
        • Holmboe E.S.
        • et al.
        A statewide initiative to improve the care of hospitalized pneumonia patients: the Connecticut Pneumonia Pathway Project.
        Am J Med. 2001; 111: 203-210
        • Centers for Disease Control and Prevention, US Department of Health and Human Services
        International Classification of Diseases, Ninth Revision, Clinical Modification.
        US Department of Health and Human Services, Washington, DC2009
        • Whittle J.
        • Fine M.J.
        • Joyce D.Z.
        • et al.
        Community-acquired pneumonia: can it be defined with claims data?.
        Am J Med Qual. 1997; 12: 187-193
        • Yealy D.M.
        • Auble T.E.
        • Stone R.A.
        • et al.
        Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial.
        Ann Intern Med. 2005; 143: 881-894
        • Elixhauser A.
        • Steiner C.
        • Harris D.R.
        • Coffey R.M.
        Comorbidity measures for use with administrative data.
        Med Care. 1998; 36: 8-27
        • Iezzoni L.I.
        • Foley S.M.
        • Daley J.
        • Hughes J.
        • Fisher E.S.
        • Heeren T.
        Comorbidities, complications, and coding bias.
        JAMA. 1992; 267: 2197-2203
        • Macfarlane J.T.
        • Finch R.G.
        • Ward M.J.
        • Macrae A.D.
        Hospital study of adult community-acquired pneumonia.
        Lancet. 1982; 2: 255-258
        • Marrie T.J.
        • Durant H.
        • Yates L.
        Community-acquired pneumonia requiring hospitalization: 5-year prospective study.
        Rev Infect Dis. 1989; 11: 586-599
        • Jackson L.A.
        • Neuzil K.M.
        • Yu O.
        • et al.
        Effectiveness of pneumococcal polysaccharide vaccine in older adults.
        N Engl J Med. 2003; 348: 1747-1755
        • Vila-Corcoles A.
        • Ochoa-Gondar O.
        • Hospital I.
        • et al.
        Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
        Clin Infect Dis. 2006; 43: 860-868
        • Spaude K.A.
        • Abrutyn E.
        • Kirchner C.
        • Kim A.
        • Daley J.
        • Fisman D.N.
        Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia.
        Arch Intern Med. 2007; 167: 53-59
        • Centers for Disease Control
        Pneumococcal polysaccharide vaccine.
        MMWR Morb Mortal Wkly Rep. 1989; 38 (73-76): 64-68
        • Fedson D.S.
        Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996.
        Clin Infect Dis. 1998; 26: 1117-1123
      1. Influenza and pneumococcal vaccination coverage levels among persons aged>or=65 years—United States, 1973-1993.
        MMWR Morb Mortal Wkly Rep. 1995; 44 (513-515): 506-507
        • Fedson D.S.
        Influenza and pneumococcal vaccination in Canada and the United States, 1980-1993: what can the two countries learn from each other?.
        Clin Infect Dis. 1995; 20: 1371-1376
        • Moberley S.A.
        • Holden J.
        • Tatham D.P.
        • Andrews R.M.
        Vaccines for preventing pneumococcal infection in adults.
        Cochrane Database Syst Rev. 2008; : CD000422
        • Macfarlane J.T.
        Treatment of lower respiratory infections.
        Lancet. 1987; 2: 1446-1449
        • Niederman M.S.
        • Bass Jr, J.B.
        • Campbell G.D.
        • et al.
        Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association.
        Am Rev Respir Dis. 1993; 148: 1418-1426
        • Mandell L.A.
        • Wunderink R.G.
        • Anzueto A.
        • et al.
        Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.
        Clin Infect Dis. 2007; 44: S27-S72
        • Frei C.R.
        • Restrepo M.I.
        • Mortensen E.M.
        • Burgess D.S.
        Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia.
        Am J Med. 2006; 119: 865-871
        • Garcia Vazquez E.
        • Mensa J.
        • Martinez J.A.
        • et al.
        Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone.
        Eur J Clin Microbiol Infect Dis. 2005; 24: 190-195
        • Gleason P.P.
        • Meehan T.P.
        • Fine J.M.
        • Galusha D.H.
        • Fine M.J.
        Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.
        Arch Intern Med. 1999; 159: 2562-2572
        • Hueston W.J.
        • Schiaffino M.A.
        Antibiotic choice and patient outcomes in community-acquired pneumonia.
        J Am Board Fam Pract. 1994; 7: 95-99
        • Thomsen R.W.
        • Riis A.
        • Kornum J.B.
        • Christensen S.
        • Johnsen S.P.
        • Sorensen H.T.
        Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients.
        Arch Intern Med. 2008; 168: 2081-2087
        • Chopra V.
        • Flanders S.A.
        Does statin use improve pneumonia outcomes?.
        Chest. 2009; 136: 1381-1388
        • Tleyjeh I.M.
        • Kashour T.
        • Hakim F.A.
        • et al.
        Statins for the prevention and treatment of infections: a systematic review and meta-analysis.
        Arch Intern Med. 2009; 169: 1658-1667
        • Viasus D.
        • Garcia-Vidal C.
        • Gudiol F.
        • Carratala J.
        Statins for community-acquired pneumonia: current state of the science.
        Eur J Clin Microbiol Infect Dis. 2010; 29: 143-152
        • Suh D.C.
        • Lau H.
        • Pokras S.M.
        • Choi I.S.
        • Valiyeva E.
        Sex differences in ambulatory visits for chronic obstructive pulmonary disease, based on the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey from 1995 to 2004.
        Respir Care. 2008; 53: 1461-1469
        • Centers for Disease Control and Prevention. Seasonal influenza (flu): flu activity & surveillance
        (Last accessed April 15, 2010)
        • Metersky M.L.
        • Tate J.P.
        • Fine M.J.
        • Petrillo M.K.
        • Meehan T.P.
        Temporal trends in outcomes of older patients with pneumonia.
        Arch Intern Med. 2000; 160: 3385-3391